NewAmsterdam Pharma (NAMS) Long-Term Investments (2025 - 2026)
NewAmsterdam Pharma (NAMS) posted Long-Term Investments of $71.2 million for Q1 2026, down 23.08% sequentially from $92.6 million in Q4 2025.
Powered by 
Analysis
NewAmsterdam Pharma (NAMS) Long-Term Investments (2025 - 2026) Analysis & Trends
NewAmsterdam Pharma has reported Long-Term Investments for 2 years, with the latest figure at $71.2 million in Q1 2026.
- Quarterly Long-Term Investments changed N/A year-over-year to $71.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $71.2 million (changed N/A YoY) and the FY2025 annual result came in at $92.6 million, changed N/A from the prior year.
- Long-Term Investments fell to $71.2 million in Q1 2026 per NAMS's latest filing, from $92.6 million in the prior quarter.
- Over five years, Long-Term Investments peaked at $92.6 million in Q4 2025 and troughed at $44.2 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -4.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 1.77 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.17 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 372.10 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | NewAmsterdam Pharma | 3.13 Bn | 3.13 Bn | - | 44.41 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 44.41 Mn |
| Mar 31, 2026 | 71.24 Mn |
| Dec 31, 2025 | 92.61 Mn |
| Sep 30, 2025 | 53.09 Mn |
| Jun 30, 2025 | 44.17 Mn |